Holen Sie sich die Stockscreener-App
14.28
5.71%
0.625
Schlusskurs vom Vortag:
$13.65
Offen:
$13.77
24-Stunden-Volumen:
30,443
Relative Volume:
0.41
Marktkapitalisierung:
$355.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.45M
KGV:
-
EPS:
-
Netto-Cashflow:
$-33.15M
1W Leistung:
-20.50%
1M Leistung:
-10.21%
6M Leistung:
-9.81%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.49
$14.51
1-Wochen-Bereich:
$12.33
$18.19
52-Wochen-Spanne:
$12.33
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Firmenname
Contineum Therapeutics Inc
Sektor
Branche
Telefon
(858) 333-5280
Adresse
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Vergleichen Sie CTNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CTNM | 14.29 | 355.48M | 0 | -31.45M | -33.15M | 0.00 |
| VRTX | 450.66 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.72 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.27 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.44 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.30 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum Therapeutics chief scientific officer sells $101,420 in stock - Investing.com
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - BioSpace
Contineum Therapeutics Secures FDA Authorization for Novel Pain Treatment PIPE-791 | CTNM Stock News - StockTitan
(CTNM) Trading Signals - Stock Traders Daily
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation - Yahoo Finance
Contineum Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Contineum Therapeutics Announces Financial Results for the Quarter Ended September 30, 2024 - Defense World
Contineum Therapeutics' SWOT analysis: promising pipeline drives stock outlook - Investing.com India
Contineum Therapeutics (NASDAQ:CTNM) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Royal Bank of Canada Lowers Contineum Therapeutics (NASDAQ:CTNM) Price Target to $31.00 - MarketBeat
Ionis to present at upcoming investor conferences - Quantisnow
(CTNM) Trading Report - Stock Traders Daily
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - BioSpace
Contineum (CTNM) Reports Strong Trial Progress, $214M Cash Runway Through 2027 | CTNM Stock News - StockTitan
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - Quantisnow
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
(CTNM) Proactive Strategies - Stock Traders Daily
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Upgraded by Baird R W - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Upgraded at Baird R W - MarketBeat
Ionis to hold third quarter 2024 financial results webcast - Quantisnow
Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials - Investing.com Canada
Contineum stock draws bullish view at Baird (CTNM:NASDAQ) - Seeking Alpha
Contineum Therapeutics (NASDAQ:CTNM) Research Coverage Started at Robert W. Baird - MarketBeat
Baird bullish on Contineum Therapeutics stock, sees upside from early-stage trials By Investing.com - Investing.com South Africa
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow
EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow
Objective long/short (CTNM) Report - Stock Traders Daily
The US IPO Engine Looks Ready to Speed Ahead in Second Quarter - MSN
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28% - Yahoo Finance
Financial Metrics Exploration: Understanding Contineum Therapeutics Inc. (CTNM) Through Ratios - The Dwinnex
Squarepoint Ops LLC Invests $2.64 Million in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
SEC Form 4 filed by EVP, Chief Human Resourses Ofc Devers Shannon L. - Quantisnow
New insider Devers Shannon L. claimed ownership of 7,909 shares (SEC Form 3) - Quantisnow
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum - Yahoo Finance
Rhumbline Advisers Makes New Investment in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Trading 5% Higher - Defense World
Perceptive Advisors LLC Purchases Shares of 1,566,668 Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
Wall Street SWOT: Contineum Therapeutics stock rides wave of promising assets - Investing.com
Bank of New York Mellon Corp Invests $356,000 in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Sandia Investment Management LP Takes $88,000 Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc.'s Lock-Up Period Will End on October 2nd (NASDAQ:CTNM) - MarketBeat
Contineum Therapeutics, Inc.'s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - MarketBeat
CD Projekt (OTCMKTS:OTGLY) Shares Up 2.8% - Defense World
Contineum Therapeutics, Inc.’s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - Defense World
BW LPG (OTCMKTS:BWLLY) Stock Price Down 0.1% - Defense World
NET Power Inc. (NYSE:NPWR) Major Shareholder Sells $12,348.00 in Stock - Defense World
Direxion Daily MSFT Bull 2X Shares Announces Quarterly Dividend of $0.33 (NASDAQ:MSFU) - Defense World
Hilton Worldwide Holdings Inc. (NYSE:HLT) Shares Acquired by Xponance Inc. - Defense World
Finanzdaten der Contineum Therapeutics Inc-Aktie (CTNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):